首页> 外文期刊>Hepato-gastroenterology. >The hemostatic effect of endoscopic sodium hyaluronate injection in peptic ulcer bleeding.
【24h】

The hemostatic effect of endoscopic sodium hyaluronate injection in peptic ulcer bleeding.

机译:内镜透明质酸钠注射液在消化性溃疡出血中的止血作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: Endoscopic injection therapy is a well-established method of controlling peptic ulcer bleeding but it is not clear which agent would be the best choice for injection material. In this study, we evaluated the effect of Sodium Hyaluronate for control of ulcer bleeding. METHODOLOGY: The subjects consisted of 26 patients with major peptic ulcer hemorrhage from June 2000 to August 2001. There were 17 gastric ulcers, 7 duodenal ulcers and 2 ulcers at anastomosis site. According to modified Forrest classifications, there were 7 active bleeding (spurting, 3; oozing, 4) and 19 stigmata of recent hemorrhage (visible vessel, 14; fresh blood clots, 5). Sodium Hyaluronate-saline solution was injected to control the bleeding. The initial and permanent hemostatic rate, rebleeding rate, and other complications were retrospectively evaluated. RESULTS: The initial hemostatic rate was 25/26 (96.2%) and re-bleeding rate 3/26 (11.5%). The success rate of the second trial of Sodium Hyaluronate injection was3/3 (100%). Overall, the permanent hemostatic rate was 25/26 (96.2%) and there were no complications related to Sodium Hyaluronate injection. CONCLUSIONS: Sodium Hyaluronate is an excellent candidate agent for endoscopic injection therapy because of its convenience and safety. Further prospective randomized trials with other hemostatic methods are needed.
机译:背景/目的:内窥镜注射疗法是控制消化性溃疡出血的行之有效的方法,但尚不清楚哪种药物是注射材料的最佳选择。在这项研究中,我们评估了透明质酸钠对控制溃疡出血的作用。方法:从2000年6月至2001年8月,该科共收治26例重大消化性溃疡出血患者。在吻合部位有17例胃溃疡,7例十二指肠溃疡和2例溃疡。根据改良的Forrest分类,有7例活动性出血(喷出3例;渗出4例)和19例近期出血的柱头(可见血管14例;新鲜血块5例)。注射透明质酸钠盐溶液以控制出血。回顾性评估初始和永久止血率,再出血率和其他并发症。结果:初始止血率为25/26(96.2%),再出血率为3/26(11.5%)。透明质酸钠注射液第二次试验的成功率为3/3(100%)。总体而言,永久止血率为25/26(96.2%),并且没有与透明质酸钠注射液相关的并发症。结论:透明质酸钠由于其方便性和安全性,是内镜注射治疗的极佳候选药物。需要使用其他止血方法进行进一步的前瞻性随机试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号